DSL(SH:603233)2021-10-27 16:00Financial Performance - The company's revenue for Q3 2021 reached ¥4,300,515,279.65, representing a year-over-year increase of 21.08%[3] - Net profit attributable to shareholders decreased by 36.59% to ¥172,682,590.21 in Q3 2021[3] - The basic earnings per share (EPS) fell by 37.36% to ¥0.22 for the quarter[4] - Total revenue for the first three quarters of 2021 reached ¥12,355,070,179.61, an increase from ¥10,492,222,853.65 in the same period of 2020, representing a growth of approximately 17.8%[28] - Net profit for the third quarter of 2021 was ¥828,833,645.21, a decrease from ¥880,751,721.07 in the same quarter of 2020, reflecting a decline of approximately 5.9%[30] - The company’s operating profit for the third quarter of 2021 was ¥1,081,970,381.63, a decrease from ¥1,186,379,200.34 in the same quarter of 2020, indicating a decline of about 8.8%[30] - Total comprehensive income for Q3 2021 was approximately ¥828.83 million, a decrease from ¥880.75 million in Q3 2020, representing a decline of about 5.9%[31] - Basic earnings per share for Q3 2021 was ¥1.04, down from ¥1.10 in Q3 2020, indicating a decrease of approximately 5.5%[31] Assets and Liabilities - Total assets increased by 30.47% to ¥16,088,905,656.46 compared to the end of the previous year[4] - The company's total assets as of the third quarter of 2021 amounted to ¥16,088,905,656.46, up from ¥12,331,926,019.36 in the previous year, marking an increase of about 30.5%[26] - Non-current liabilities totaled ¥4,062,797,526.32 in the third quarter of 2021, significantly higher than ¥1,290,556,310.46 in the same period of 2020, representing an increase of approximately 214%[26] - The company's total liabilities reached ¥10,213,605,247.67 in the third quarter of 2021, compared to ¥6,759,026,117.38 in the previous year, reflecting an increase of about 50.5%[26] - Cash and cash equivalents decreased to ¥142,028,155.43 from ¥190,859,323.15 year-over-year, a decline of about 25.5%[26] - Shareholders' equity was reported at $5.57 billion, a decline of $175.47 million from the previous period[37] - The company’s retained earnings increased to $2.63 billion, up by $171.95 million from the previous period[37] Research and Development - The company reported a significant increase in R&D expenses by 829.15%, primarily due to investments in internet development[8] - The company reported research and development expenses of ¥9,466,867.25 for the first three quarters of 2021, a substantial increase from ¥1,018,870.01 in the same period of 2020, indicating a growth of approximately 828%[29] Cash Flow - Cash flow from operating activities for the year-to-date period was ¥1,222,215,126.93, down 9.02% compared to the previous year[3] - Net cash flow from operating activities for the first three quarters of 2021 was ¥1.22 billion, compared to ¥1.34 billion in the same period of 2020, reflecting a decline of about 9.0%[33] - Cash inflow from operating activities totaled ¥14.16 billion for the first three quarters of 2021, an increase of approximately 16.0% from ¥12.18 billion in 2020[32] - Cash outflow for operating activities was ¥12.93 billion in the first three quarters of 2021, up from ¥10.84 billion in 2020, representing an increase of about 19.4%[33] - Investment activities generated a net cash outflow of approximately ¥636.88 million in the first three quarters of 2021, compared to a net inflow of ¥32.38 million in the same period of 2020[33] - The company received cash from investment activities totaling approximately ¥2.28 billion in the first three quarters of 2021, an increase from ¥2.08 billion in 2020, reflecting a growth of about 9.6%[33] - The company reported cash inflow from financing activities of approximately ¥144.19 million in the first three quarters of 2021, down from ¥184.36 million in 2020, indicating a decrease of about 21.8%[33] Mergers and Acquisitions - The company completed 29 mergers and acquisitions in the industry during the reporting period, with 9 from previous years finalized and 20 new projects signed, involving a total of 839 stores[13] - The company invested CNY 94.61 million to acquire a 51% stake in a new company formed from the integration of 5 stores, with the project completed in March 2021[13] - A total of CNY 13.42 million was spent to acquire a 51% stake in a new company formed from 10 stores, with the project completed in April 2021[14] - The company acquired assets and businesses of 7 stores for CNY 15 million, with the project completed in January 2021[14] - The company invested CNY 25.85 million to increase its stake to 61% in a company, involving 21 stores, with the project completed in September 2021[15] - A total of CNY 38.29 million was used to acquire 100% of a company, involving 17 stores, with the project completed in February 2021[15] - The company spent CNY 42.96 million to acquire a 65% stake in a company, involving 39 stores, with the project completed in March 2021[15] - The company acquired a 56% stake in another company for CNY 23.31 million, involving 26 stores, with the project completed in July 2021[16] - The company is in the process of acquiring a 51% stake in a pharmacy chain for a total of CNY 9.17 million, involving 129 stores[17] - The company invested CNY 68.34 million to acquire a 51% stake in a pharmacy chain, involving 59 stores, with the project completed in April 2021[17] - The company acquired 51% of Deyang Dacheng Family Health Chain Pharmacy for CNY 31.53 million, involving 49 stores, with the project ongoing[18] - The company completed the acquisition of 51% of Huishan County Runkang Plaza Pharmaceutical Chain for CNY 37.31 million, involving 33 stores, in September 2021[18] - The company acquired 56% of Qiqihar Xinte Pharmaceutical Chain for CNY 23.22 million, involving 18 stores, with the project completed in June 2021[18] - The company is in the process of acquiring 56% of Xi'an Wanbaiquan Pharmaceutical for CNY 46.90 million, involving 55 stores[18] - The company completed the acquisition of 51% of Yangzhou Baixingrenjia Pharmaceutical Chain for CNY 12.71 million, involving 14 stores, in August 2021[19] - The company acquired tangible and intangible assets of 20 stores from Meizhou Yimin Pharmacy for CNY 15 million, with the project completed in September 2021[19] - The company completed the acquisition of 56% of Daqing Foster Pharmaceutical Chain for CNY 26.47 million, involving 18 stores, in August 2021[20] - The company is in the process of acquiring 100% of Hebei Yibao Pharmaceutical Technology for CNY 10 million, which has drug wholesale qualifications[20] - The company is in the process of acquiring 51% of a new pharmaceutical chain company with 48 stores, for CNY 29.87 million[22] - The company is in the process of acquiring 70% of Heilongjiang Taihua Pharmaceutical Chain for CNY 125.85 million, involving 85 stores[23]